December 2012

Physiomics plc (AIM: PYC), the Oxford, UK based systems biology company, is pleased to announce that it has been recognised by the French Ministry of Higher Education and Research as an eligible research organisation for French companies seeking to claim French Research and Development tax credits (“Agrément crédit d’impôt recherche") on their research projects (2012 to 2014). Read more...

Read More

Chairman’s Statement   Summary of Results in the year ended 30 June 2012   Fundraising in April 2012 generated cash of £555,000 before issue expenses. The turnover of the Company more than doubled to £135,306 (2011: £53,345). The operating loss reduced to £577,922 (2011: £693,795). On 30 June 2012 the surplus of shareholders’ funds was £734,570 (2011: £755,511). With a now fully validated Virtual Tumour technology, Physiomics has concentrated...

Read More

Further to the announcement that a poster will be shown at the PKUK 2012 meeting, Dr Eric Fernandez will give a talk at the conference on the Friday 11th of November, entitled "A database of PK-PD parameters and information for the modelling of anti-cancer treatment regimens and drug combinations". Please click here for more information on the conference. ...

Read More

Physiomics plc (AIM: PYC), the Oxford, UK based systems biology company, is pleased to announce that Dr. David Jobes will be joining the company as Business Development Consultant.  David is based on the East Coast of the USA. Read more...

Read More

Dr Frances Brightman has been accepted for a poster presentation at PKUK 2012 meeting. Frances will show an update on the anti cancer drug combination database research program. Please click here for more information on the conference. ...

Read More

Physiomics will present on “Modelling the responses of populations of cancer cells to therapeutic radiation exposure”, on 5th September at the 5th International Systems Radiation Biology Workshop in Oxford.  Professor David Fell, Co-Founder and Scientific Advisory Board member, will show recent applications of the Virtual Tumour platform to forecast the outcome of combinations of radiation treatment with an anti-cancer drug. ...

Read More

Physiomics will present a workshop on “Applications of Physiomics’ Virtual Tumour to optimize the outcomes of xenograft experiments”, on 27th November at the 4th PK/PD Summit in Frankfurt. This workshop will review the available PK/PD models to simulate and analyze xenograft experiments and will present the features and the scientific and economic benefits of Physiomics’ Virtual Tumour cell population model. The workshop will include the...

Read More

Physiomics is an AIM – listed Oxford-based systems biology company specialised in computational modelling of complex biological systems. Our Virtual Tumour technology is used by pharmaceutical and biotechnology companies to optimise drug dosing and scheduling regimens for pre-clinical studies.  The company is now starting to develop a clinical version of Virtual Tumour to optimise regimens in human patients. We seek to recruit a Senior Scientist...

Read More

The Company announces that it has raised £555,000 from the issue of 370,000,000 new ordinary shares of 0.04p each ("Ordinary Shares") at a price of 0.15p per share, by way of a placing through WH Ireland Limited (the "Placing"). Application has been made for the new Ordinary Shares to be admitted to trading on AIM and dealings are expected to commence on 2 May 2012...

Read More